Working party membership and contributors

From Cancer Guidelines Wiki

Working party membership and contributors to guidelines and public consultation submissions received

Management Committee

Member name Position
Professor John Thompson AO Executive Director, Melanoma Institute Australia (until December 2016); Senior Surgeon, Melanoma Institute Australia; Professor of Melanoma and Surgical Oncology, The University of Sydney
Professor Michael Henderson Professor of Surgery, University of Melbourne; Co-Chair, Melanoma and Skin Service, Peter MacCallum Cancer Centre, VIC
Professor John Kelly Dermatologist and Head, Victorian Melanoma Service, Alfred Hospital
Professor Georgina Long Co-Medical Director, Melanoma Institute Australia (from December 2016); Medical Oncologist and Associate Professor of Melanoma Biology and Translational Research, Melanoma Institute Australia and The University of Sydney, NSW
A/Professor Susan Neuhaus General Surgeon and Surgical Oncologist, Royal Adelaide Hospital; Clinical Associate Professor, University of Adelaide Department of Surgery; Associate Professor, Conflict Medicine, University of Adelaide, SA
Dr Annette Pflugfelder PhD Student, Dermatology Research Centre, School of Medicine, The University of Queensland
Professor Richard Scolyer Co-Medical Director, Melanoma Institute Australia (from December 2016); Clinical Professor, Pathology, The University of Sydney, NSW
Professor Graham Stevens Director of Radiation Oncology, Orange General Hospital, NSW
Jutta von Dincklage Head, Clinical Guidelines Network (until November 2016)
Laura Wuellner Acting Head, Clinical Guidelines Network (from November 2016)

For details of Working Party authorship and subcommittee membership, please see the List of clinical questions.

Membership: Multi-disciplinary Working Party

The Management Committee established a multi-disciplinary working party to develop these guidelines.

The multi-disciplinary Working Party consists of the Management Committee members, the lead authors for guideline sections, consumer representatives as well as the Cancer Council Australia Project team members.

Role Member name Specialty/position State
Management Committee member, Chair of working party Professor John Thompson AO Executive Director, Melanoma Institute Australia (until December 2016); Senior Surgeon, Melanoma Institute Australia; Professor of Melanoma and Surgical Oncology, The University of Sydney NSW
Lead Author A/Professor Andrew Barbour General Surgeon, Greenslopes Private Hospital, Princess Alexandra Hospital, QLD QLD
Lead Author Dr Matteo Carlino Medical Oncologist Westmead and Blacktown Hospitals, Melanoma institute Australia

Clinical Senior lecturer University of Sydney

NSW
Lead Author Dr David Gyorki Consultant Surgeon, Peter MacCallum Centre VIC
Management Committee member

Lead Author

Professor Michael Henderson Professor of Surgery, University of Melbourne; Co-Chair, Melanoma and Skin Service, Peter MacCallum Cancer Centre, VIC VIC
Lead Author A/Professor Angela Hong Radiation Oncologist, Melanoma Institute Australia; Clinical Associate Professor, Medicine, The University of Sydney NSW
Lead Author Dr Julie Howle Clinical Senior Lecturer, Surgery, The University of Sydney NSW
Lead Author A/Professor T Michael Hughes Associate Professor, Surgery, The University of Sydney; Surgeon, Sydney Adventist Hospital NSW
Lead Author Professor Richard Kefford AM Professor of Cancer Medicine, Macquarie University NSW
Management Committee member

Lead Author

Professor John Kelly Dermatologist and Head, Victorian Melanoma Service, Alfred Hospital NSW
Management Committee member

Lead Author

Professor Georgina Long Executive Director, Melanoma Institute Australia (until December 2016); Senior Surgeon, Melanoma Institute Australia; Professor of Melanoma and Surgical Oncology, The University of Sydney NSW
Lead Author Professor Graham Mann Chair, University of Sydney Cancer Research Network and Cancer SPARC Steering Committee; Co-Director, Centre for Cancer Research, Westmead Millennium Institute; Research Director, Melanoma Institute Australia, NSW NSW
Lead Author Dr Victoria Mar Dermatologist, Armadale Dermatology, NSW NSW
Lead Author Professor Scott Menzies The Sydney Melanoma Diagnostic Centre, Royal Prince Alfred Hospital; Professor, Discipline of Dermatology, The University of Sydney NSW
Lead Author Professor Michael Millward Professor of Clinical Cancer Research, The University of Western Australia; Consultant Medical Oncologist, Sir Charles Gardiner Hospital WA
Lead Author Dr Rachael Morton Director of Health Economics, NHMRC Clinical Trials Centre, The University of Sydney NSW
Management Committee member A/Professor Susan Neuhaus General Surgeon and Surgical Oncologist, Royal Adelaide Hospital; Clinical Associate Professor, University of Adelaide Department of Surgery; Associate Professor, Conflict Medicine, University of Adelaide SA
Management Committee member Dr Annette Pflugfelder Research Higher Degree Student, The School of Medicine, The University of Queensland QLD
Lead Author Dr Robyn Saw Senior Lecturer, Surgery, The University of Sydney; Surgical Oncologist; General Surgeon, Melanoma Institute Australia and Royal Prince Alfred & Mater Hospitals NSW
Management Committee member Professor Richard Scolyer Co-Medical Director, Melanoma Institute Australia (from December 2016); Clinical Professor, Pathology, The University of Sydney, NSW NSW
Lead Author A/Professor Michael Sladden Dermatologist, Tas Derm TAS
Lead Author Professor H Peter Soyer Director, School of Medicine, University of Queensland QLD
Lead Author A/Professor Andrew Spillane Associate Professor, Surgical Oncology, The University of Sydney NSW
Management Committee member

Lead Author

Professor Graham Stevens Director of Radiation Oncology, Orange General Hospital NSW
GP representative Dr Margaret Hardy General practitioner Gladesville Medical NSW
GP representative Dr Paul Fishburn General practitioner NSW
Consumer representative Alison Button-Sloan Consumer representative VIC
Consumer representative Clinton Heal Consumer, CEO and Founder, Melanoma WA, 2011 WA Young Australian of the Year WA
Management Committee member

CCA Project Team Lead

Jutta von Dincklage Head, Clinical Guidelines Network (until November 2016) NSW
Management Committee member

CCA Project Team Lead

Laura Wuellner Acting Head, Clinical Guidelines Network (from November 2016) NSW

Cancer Council Australia Project Team

Role Member name Specialty/position State
CCA Project Team member Laura Wuellner Project Manager, Clinical Guidelines Network (until November 2016); Acting Head, Clinical Guidelines Network (from November 2016) NSW
CCA Project Team member Katrina Anderson Project Manager, Clinical Guidelines Network (from November 2016) NSW
CCA Systematic Literature Reviewer Team member Lani Teddy Project Officer, Systematic Literature Reviews, Melanoma Guidelines (until December 2016) NSW
CCA Systematic Literature Reviewer Team member Lyndal Alchin Project Officer, Systematic Literature Reviews, Melanoma Guidelines (until December 2016) NSW
CCA Systematic Literature Reviewer Team member Tamsin Parrish Project Officer, Systematic Literature Reviews, Melanoma Guidelines (from June 2016) NSW
CCA Systematic Literature Reviewer Team member (from April 2015-April 2016) Jackie Buck Project Officer, Systematic Literature Reviews, Melanoma Guidelines (until April 2016) NSW
CCA Systematic Literature Reviewer Team member (from April 2015-April 2016) Meghna Kakani Project Officer, Systematic Literature Reviews, Melanoma Guidelines (from January 2017) NSW
CCA Systematic Literature Reviewer Team member (from April 2015-April 2016) Cecilia Taing Project Officer, Systematic Literature Reviews, Melanoma Guidelines (from January 2017) NSW

Sub-committee membership for each guideline question

For each guideline question, the guideline question lead author under consultation with the Management Committee established a sub-committee with relevant expert members of the working party and co-opted additional external clinical experts as required.

The role of the sub-committee is to review the draft content for the guideline questions of the section before it is presented to the working party.

WHAT ARE THE CLINICAL FEATURES OF MELANOMA AND HOW DO ATYPICAL MELANOMAS PRESENT?
Question lead: Victoria Mar
Sub-committee members
Name Position/speciality
Dr Alex Chamberlain Dermatologist, The Alfred Hospital, VIC
Professor Stephen Lee AM Professor of Dermatology, The University of Sydney, NSW
Dr Bill Murray Head of Anatomical Pathology, Peter MacCallum Cancer Centre, VIC
Professor John Kelly Dermatologist and Head, Victorian Melanoma Service, Alfred Hospital

Back to top

WHAT TYPE OF BIOPSY SHOULD BE PERFORMED FOR A SUSPICIOUS PIGMENTED SKIN LESION?
Question lead: Professor John Kelly
Sub-committee members
Name Position/speciality
Dr Trevor Beer Histopathologist, Clinipath Pathology, WA
Professor Diona Damian Professor of Dermatology, The University of Sydney, NSW
Jonathan Ng Honorary Research Fellow, Victorian Melanoma Service, The Alfred Hospital, VIC
Dr Joseph Ohana GP, The Village Medical Practice, NSW
Professor Richard Scolyer Co-Medical Director, Melanoma Institute Australia (from December 2016); Clinical Professor, Pathology, The University of Sydney, NSW
Professor H Peter Soyer Director, School of Medicine, University of Queensland, QLD


Back to top

WHEN IS A SENTINEL NODE BIOPSY INDICATED?
Question lead: Dr David Gyorki
Sub-committee members
Name Position/speciality
A/Professor Andrew Barbour General Surgeon, Greenslopes Private Hospital, Princess Alexandra Hospital, QLD
Dr Victoria Mar Dermatologist Armadale Dermatology, NSW
Dr Mark Hanikeri Director, Western Australia Plastic Surgery Centre, WA
Dr Shahneen Sandhu Medical Oncologist, Peter MacCallum Cancer Centre, VIC


Back to top

WHAT ARE THE RECOMMENDED DEFINITIVE MARGINS FOR EXCISION OF PRIMARY MELANOMA?
Question lead: A/Professor Michael Sladden
Sub-committee members
Name Position/speciality
Dr Julie Howle Clinical Senior Lecturer, Surgery, The University of Sydney, NSW
Professor Omgo Nieweg Surgeon, Melanoma Institute Australia, NSW


Back to top

WHAT IS THE ROLE OF DERMOSCOPY (AND SEQUENTIAL DERMOSCOPY) IN MELANOMA DIAGNOSIS?
Question lead: Professor Scott Menzies
Sub-committee members
Name Position/speciality
Dr Alex Chamberlain Dermatologist, The Alfred Hospital, VIC
A/Professor Pascale Guitera Senior Research Fellow, Dermatology, The University of Sydney, NSW
Professor H Peter Soyer Director, School of Medicine, University of Queensland, QLD

Back to top

WHAT IS THE APPROPRIATE TREATMENT FOR MACROSCOPIC (I.E. DETECTABLE CLINICALLY OR BY ULTRASOUND) NODAL METASTASIS?
Question lead: Professor Michael Henderson
Sub-committee members
Name Position/speciality
A/Professor T Michael Hughes Associate Professor, Surgery, The University of Sydney; Surgeon, Sydney Adventist Hospital, NSW
A/Professor Mark Smithers Associate Professor, Department of Surgery, The University of Queensland, QLD
A/Professor Andrew Spillane Associate Professor, Surgical Oncology, The University of Sydney
Dr John Spillane General Surgeon, Epworth Eastern Consulting, VIC


Back to top

SHOULD ALL PATIENTS WITH A POSITIVE SENTINEL LYMPH NODE BIOPSY HAVE A COMPLETE NODE DISSECTION?
Question lead: A/Professor Andrew Spillane
Sub-committee members
Name Position/speciality
Dr Frank Bruscino-Raiola Consultant Plastic Surgeon, Alfred Health, VIC
Dr David Gyorki Consultant Surgeon, Peter MacCallum Centre, VIC
Dr Julie Howle Senior Lecturer, Surgery, The University of Sydney, NSW
Dr Chris McCormack Consultant Dermatologist, St Vincents Hospital Melbourne, VIC
A/Professor Mark Smithers Associate Professor, Department of Surgery, The University of Queensland, QLD


Back to top

WHAT INVESTIGATIONS SHOULD BE PERFORMED FOLLOWING A DIAGNOSIS OF PRIMARY CUTANEOUS MELANOMA FOR ASYMPTOMATIC STAGE I AND II PATIENTS?
Question lead: Dr Rachael Morton
Sub-committee members
Name Position/speciality
A/Professor Andrew Barbour General Surgeon, Greenslopes Private Hospital, Princess Alexandra Hospital, QLD
Dr Victoria Mar Dermatologist, Armadale Dermatology, NSW
A/Professor Mark Smithers Associate Professor, Department of Surgery, The University of Queensland, QLD
A/Professor Jonathan Stretch AM Associate Professor of Melanoma and Skin Oncology, The University of Sydney, NSW


Back to top

WHAT INVESTIGATIONS SHOULD BE PERFORMED WHEN IN TRANSIT AND/OR REGIONAL NODE DISEASE (STAGE III MELANOMA) IS DIAGNOSED?
Question lead: Dr Robyn Saw
Sub-committee members
Name Position/speciality
Dr Andrew Haydon Medical Oncologist, Alfred Hospital and Cabrini Health, VIC
Professor Grant McArthur Head, Molecular Oncology Laboratory and Translational Research Laboratory, Co-Chair, Melanoma and Skin Service, Peter MacCallum Cancer Centre, VIC
Dr Alex Menzies Medical Oncologist, Royal North Shore Hospital, NSW
Dr John Spillane General Surgeon, Epworth Eastern Consulting, VIC


Back to top

WHAT INVESTIGATIONS SHOULD BE PERFORMED WHEN STAGE IV MELANOMA IS DIAGNOSED?
Question lead:Professor Michael Millward
Sub-committee members
Name Position/speciality
Dr Victoria Atkinson Senior Staff Specialist, Princess Alexandra Hospital; Visiting Medical Oncologist, Greenslopes Private Hospital, QLD
Dr Michael Brown Medical Oncologist, Royal Adelaide Hospital, SA
Dr Andrew Haydon Medical Oncologist, Alfred Hospital and Cabrini Health, VIC
Dr Alex Menzies Medical Oncologist, Royal North Shore Hospital, NSW


Back to top

HOW SHOULD PATIENTS AT EACH STAGE OF MELANOMA BE FOLLOWED AFTER INITIAL DEFINITIVE TREATMENT?
Question lead: A/Professor Andrew Barbour
Sub-committee members
Name Position/speciality
A/Professor Alexander Guminski Associate Professor, Medicine, The University of Sydney, Medical Oncologist, Melanoma Institute Australia, North Shore Private Hospital, and Royal North Shore Hospital, NSW
Wendy Liu Dermatologist, Alfred Hospital, Peter MacCallum Cancer Centre, Victorian Melanoma Service, VIC
Professor Scott Menzies The Sydney Melanoma Diagnostic Centre, Royal Prince Alfred Hospital; Professor, Discipline of Dermatology, The University of Sydney, NSW
Dr Rachael Morton Senior Research Fellow, Public Health, The University of Sydney, NSW

Back to top

WHO IS AT HIGH RISK OF MELANOMA?
Question lead: Professor Graham Mann
Sub-committee members
Name Position/speciality
Dr Anne Cust Senior Research Fellow, Public Health, The University of Sydney, NSW
Professor Diona Damian Professor of Dermatology, The University of Sydney, NSW
Professor H Peter Soyer Director, School of Medicine, University of Queensland, QLD
Professor David Whiteman Senior Principal Research Fellow and Head, Cancer Control, Queensland Institute of Medical Research Berghofer Medical Research Institute, QLD
Dr Paul Fishburn GP, The Village Medical Practice, NSW
Professor John Kelly Dermatologist and Head, Victorian Melanoma Service, Alfred Hospital
Dr Rachael Morton Senior Research Fellow, Public Health, The University of Sydney, NSW
Dr Victoria Mar Dermatologist, Armadale Dermatology, NSW


Back to top

WHAT CLINICAL INFORMATION SHOULD THE PATHOLOGIST GIVE THE CLINICIAN TO AID DIAGNOSIS OF MELANOMA?
Question lead: Dr Craig James
Sub-committee members
Name Position/speciality
A/Professor Brendon Coventry Associate Professor, Department of Surgery, The University of Adelaide; Senior Consultant Surgeon, Royal Adelaide Hospital, SA
Professor Richard Scolyer Co-Medical Director, Melanoma Institute Australia (from December 2016); Clinical Professor, Pathology, The University of Sydney, NSW
Professor Stephen Lee AM Professor of Dermatology, The University of Sydney, NSW
Professor Catriona McLean Director, Pathology Board, Monash University; Director, Anatomical Pathology, The Alfred Hospital, VIC


Back to top

WHAT IS THE ROLE OF ADJUVANT SYSTEMIC THERAPY IN PATIENTS WITH RESECTED STAGE 3 MELANOMA?
Question lead: Dr Matteo Carlino
Sub-committee members
Name Position/speciality
Professor Catriona McLean Director, Pathology Board, Monash University; Director, Anatomical Pathology, The Alfred Hospital, VIC
Professor Richard Kefford AM Professor of Medicine and Director, Westmead Institute for Cancer Research


Back to top

IS ADJUVANT RADIOTHERAPY OF VALUE FOLLOWING RESECTION OF INVOLVED LYMPH NODES?
Question lead: Professor Graham Stevens
Sub-committee members
Name Position/speciality
Professor Bryan Burmeister Director, Radiation Oncology, Princess Alexandra Hospital, QLD
Dr Gerald Fogarty Director, Radiation Oncology, Mater Hospital, NSW
Professor Michael Henderson Professor of Surgery, University of Melbourne; Co-Chair, Melanoma and Skin Service, Peter MacCallum Cancer Centre, VIC

Back to top

FOR PATIENTS WITH DISTANT METASTASES, WHEN IS SURGICAL THERAPY INDICATED?
Question lead: A/Prof Andrew Spillane
Sub-committee members
Name Position/speciality
A/Professor Andrew Barbour General Surgeon, Greenslopes Private Hospital, Princess Alexandra Hospital, QLD
Dr Julie Howle Clinical Senior Lecturer, Surgery, The University of Sydney, NSW


Back to top

WHAT RADIOTHERAPY IS INDICATED FOR PATIENTS WITH DISTANT METASTASES?
Question lead: A/Professor Angela Hong
Sub-committee members
Name Position/speciality
Dr Gerald Fogarty Director, Radiation Oncology, Mater Hospital, NSW
Professor Graham Stevens Director of Radiation Oncology, Orange General Hospital, NSW

Back to top

DOES SYSTEMIC DRUG THERAPY IMPROVE PROGRESSION FREE AND/OR OVERALL SURVIVAL IN STAGE 3C UNRESECTABLE AND STAGE 4 MELANOMA?
Question lead: Professor Georgina Long
Sub-committee members
Name Position/speciality
Dr Matteo Carlino Medical Oncologist, The Crown Princess Mary Cancer Centre, Westmead, NSW
Professor Richard Kefford AM Professor of Cancer Medicine, Macquarie University, NSW
Professor Grant McArthur Head, Molecular Oncology Laboratory and Translational Research Laboratory, Co-Chair, Melanoma and Skin Service, Peter MacCallum Cancer Centre, VIC
Dr Alex Menzies Medical Oncologist, Royal North Shore Hospital, NSW
Dr Mark Shackleton Group Leader, Cancer Development and Treatment Laboratory, Peter MacCallum Cancer Centre, NSW


Back to top

HOW SHOULD LENTIGO MALIGNA BE MANAGED?
Question lead: Professor H Peter Soyer
Sub-committee members
Name Position/speciality
A/Professor Pascale Guitera Senior Research Fellow, Dermatology, The University of Sydney, NSW
A/Professor Angela Hong Radiation Oncologist, Melanoma Institute Australia; Clinical Associate Professor, Medicine, The University of Sydney, NSW
Professor Richard Scolyer Co-Medical Director, Melanoma Institute Australia (from December 2016); Clinical Professor, Pathology, The University of Sydney, NSW
A/Professor Jonathan Stretch AM Associate Professor of Melanoma and Skin Oncology, The University of Sydney, NSW
Dr Geoff Strutton Anatomical Pathologist, Princess Alexandra Hospital, QLD


Back to top

SHOULD DESMOPLASTIC AND/OR NEUROTROPIC MELANOMAS BE TREATED DIFFERENTLY?
Question lead: A/Professor T Michael Hughes
Sub-committee members
Name Position/speciality
Michael Foote TBC
Professor John Kelly Dermatologist and Head, Victorian Melanoma Service, Alfred Hospital
Professor Richard Scolyer Co-Medical Director, Melanoma Institute Australia (from December 2016); Clinical Professor, Pathology, The University of Sydney, NSW
A/Professor Jonathan Stretch AM Associate Professor of Melanoma and Skin Oncology, The University of Sydney, NSW


Back to top

HOW SHOULD MELANOMA IN CHILDHOOD BE MANAGED?
Question lead: Dr Robyn Saw
Sub-committee members
Name Position/speciality
A/Professor Andrew Barbour General Surgeon, Greenslopes Private Hospital, Princess Alexandra Hospital, QLD
Dr Mark Hanikeri Director, Western Australia Plastic Surgery Centre, WA
Dr Chris McCormack Consultant Dermatologist, St Vincents Hospital Melbourne, VIC
Professor Richard Scolyer Co-Medical Director, Melanoma Institute Australia (from December 2016); Clinical Professor, Pathology, The University of Sydney, NSW


Back to top

HOW SHOULD MELANOMA IN PREGNANCY BE MANAGED?
Question lead: Dr Julie Howle
Sub-committee members
Name Position/speciality
A/Professor Kiarash Khosrotehrani Clinical Scientist, Centre for Clinical Research, The University of Queensland, QLD
Dr Robyn Saw Senior Lecturer, Surgery, The University of Sydney; Surgical Oncologist; General Surgeon, Melanoma Institute Australia and Royal Prince Alfred & Mater Hospitals, NSW

Back to top

HOW SHOULD SATELLITE AND IN TRANSIT METASTATIC DISEASE BE MANAGED?
Question lead: Professor Michael Henderson
Sub-committee members
Name Position/speciality
Professor Diona Damian Professor of Dermatology, The University of Sydney, NSW
Professor Omgo Nieweg Surgeon, Melanoma Institute Australia, NSW
Dr Robyn Saw Senior Lecturer, Surgery, The University of Sydney; Surgical Oncologist; General Surgeon, Melanoma Institute Australia and Royal Prince Alfred & Mater Hospitals, NSW
A/Professor Mark Smithers Associate Professor, Department of Surgery, The University of Queensland, QLD
Dr John Spillane General Surgeon, Epworth Eastern Consulting, VIC

Back to top

Acknowledgement

Sincere thanks to Professor Ian Olver AM who initiated the Melanoma Guidelines Revision Project in collaboration with Melanoma Institute Australia in 2014 in his role as Chief Executive Officer, Cancer Council Australia. Since February 2015, he has been Director, Sansom Institute for Health Research.

Back to top